



George Kollias

George Kollias is a Biologist, Member of the [Academy of Athens](#), Professor and Director of the Department of Physiology at the Medical School of the University of Athens and Research Professor at the Biomedical Sciences Research Center "[Alexander Fleming](#)".

Dr. Kollias has pioneered genetic approaches to study the function of cytokine signaling in animal models of human diseases, with specific focus on Tumor Necrosis Factor (TNF). His lab is renowned for proof of principle preclinical studies that led to the development of anti-TNF therapies for rheumatoid arthritis and for advancing knowledge on molecular and cellular mechanisms driving chronic inflammation and autoimmunity (e.g. Rheumatoid Arthritis, Inflammatory Bowel Disease and Multiple Sclerosis). Dr. Kollias has published over 220 primary research articles in peer-reviewed journals and more than 49 reviews and commentaries (>44.500 citations, h-index 96 Source: [Google Scholar](#)). His laboratory is supported by several competitive grants from national sources and the European Commission, and has been awarded twice (2014, 2022) the highly prestigious grants from the European Research Council ([ERC](#)).

Dr. Kollias' efforts developed almost exclusively in Greece, and his scientific and administrative work has contributed decisively to the support of a new generation of Greek scientists and the development of National Infrastructures of scientific and technological excellence. Dr. Kollias coordinates the National Research Infrastructures [Infrafrontier.GR/Phenotypos](#) from BSRC Fleming, and [pMedGR](#) from the Medical School of Athens. He is President of the Scientific Committee at the Institute of New Biotechnologies & Precision Medicine at the Medical School of Athens. In 2006 he founded the first CRO-biotech spin-off of BSRC Fleming, [Biomedcode Hellas SA](#), which offers innovative and unique models of human disease and provides preclinical drug evaluation services to large pharmaceutical companies worldwide.

Dr. Kollias is an elected member of the European Molecular Biology Organization ([EMBO](#), 2000-). Chair of the ERC Starting grants (2010-2013) and ERC Advanced Grants (2020). Dr. Kollias served as the National Representative of Greece at [ESFRI](#) (2010-2012), member of the ESFRI strategic working group on Health and Food (2011-2022) and member of the Attica Regional Council on Research and Innovation (PSEK, 2017-2022). He was elected President and Director of the Biomedical Sciences Research Center "Alexander Fleming" (2002-2010 & 2016-2020), President of the Council of the Directors of the Greek Research Centers (2009-2010) and member of the National Council on Research and Technology of the Ministry of Development (2001-2003 and 2005-2009). Since 2014, Dr. Kollias is Member of the Biosciences Steering Group of the European Academies Science Advisory Panel ([EASAC](#)). He was awarded the [Carol-Nachman Award](#) for Rheumatology (2014). Since 2016, he directs the International and Transinstitutional Graduate Program in "[Molecular Biomedicine: Mechanisms of Disease, Molecular and Cellular therapies and Bioinnovation](#)" at the Medical School of the University of Athens and the BSRC Fleming.